P2NB34 logo

Penumbra BOVESPA:P2NB34 Stock Report

Last Price

R$49.53

Market Cap

R$56.6b

7D

n/a

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials +

P2NB34 Stock Overview

Designs, develops, manufactures, and markets medical devices in the United States and internationally. More details

P2NB34 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Penumbra, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Penumbra
Historical stock prices
Current Share PriceUS$49.53
52 Week HighUS$49.65
52 Week LowUS$30.91
Beta0.52
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO23.38%

Recent News & Updates

Recent updates

Shareholder Returns

P2NB34BR Medical EquipmentBR Market
7Dn/a-1.6%-3.0%
1Yn/a7.2%-11.7%

Return vs Industry: Insufficient data to determine how P2NB34 performed against the BR Medical Equipment industry.

Return vs Market: Insufficient data to determine how P2NB34 performed against the BR Market.

Price Volatility

Is P2NB34's price volatile compared to industry and market?
P2NB34 volatility
P2NB34 Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.0%
Market Average Movement5.1%
10% most volatile stocks in BR Market9.5%
10% least volatile stocks in BR Market2.8%

Stable Share Price: P2NB34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine P2NB34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20044,200Adam Elsesserwww.penumbrainc.com

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands.

Penumbra, Inc. Fundamentals Summary

How do Penumbra's earnings and revenue compare to its market cap?
P2NB34 fundamental statistics
Market capR$56.64b
Earnings (TTM)R$210.21m
Revenue (TTM)R$7.08b

269.4x

P/E Ratio

8.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P2NB34 income statement (TTM)
RevenueUS$1.16b
Cost of RevenueUS$432.51m
Gross ProfitUS$731.27m
Other ExpensesUS$696.72m
EarningsUS$34.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.90
Gross Margin62.84%
Net Profit Margin2.97%
Debt/Equity Ratio0%

How did P2NB34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Penumbra, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Ishan MajumdarBaptista Research